Xilio Therapeutics Board Changes: New Directors Elected, Two Depart
Ticker: XLO · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1840233
Sentiment: neutral
Topics: board-changes, governance
TL;DR
Xilio board shakeup: Epstein & Earp in, Allen & Altschuler out as of June 7th.
AI Summary
On June 10, 2025, Xilio Therapeutics, Inc. filed an 8-K report detailing the departure of two directors, Dr. Jeffrey W. Allen and Dr. Steven M. Altschuler, effective June 7, 2025. The company also announced the election of two new directors, Dr. David R. Epstein and Dr. David J. Earp, to its Board of Directors, also effective June 7, 2025. These changes are part of the company's ongoing governance and strategic adjustments.
Why It Matters
Changes in a company's board of directors can signal shifts in strategy, governance, or financial direction, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty about future strategy and leadership, warranting closer observation.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- Dr. Jeffrey W. Allen (person) — Departing Director
- Dr. Steven M. Altschuler (person) — Departing Director
- Dr. David R. Epstein (person) — Newly Elected Director
- Dr. David J. Earp (person) — Newly Elected Director
- June 10, 2025 (date) — Report Date
- June 7, 2025 (date) — Effective Date of Changes
FAQ
Who has departed from Xilio Therapeutics' Board of Directors?
Dr. Jeffrey W. Allen and Dr. Steven M. Altschuler have departed from the Board of Directors.
When were the director changes effective?
The changes were effective as of June 7, 2025.
Who are the newly elected directors at Xilio Therapeutics?
Dr. David R. Epstein and Dr. David J. Earp have been elected as new directors.
What is the filing date of this 8-K report?
The report was filed on June 10, 2025.
What is the principal executive office address for Xilio Therapeutics?
The principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 by Dr. Jeffrey W. Allen regarding Xilio Therapeutics, Inc. (XLO).